Targeted Contrast Agents for Molecular MRI
Molecular magnetic resonance imaging (MRI) provides information non-invasively at cellular and molecular levels, for both early diagnosis and monitoring therapeutic follow-up. This imaging technique requires the development of a new class of contrast agents, which signal changes (typically becomes e...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-12-01
|
Series: | Inorganics |
Subjects: | |
Online Access: | https://www.mdpi.com/2304-6740/6/4/129 |
id |
doaj-c0b3316d43eb44b2a27f63b23e98b5d7 |
---|---|
record_format |
Article |
spelling |
doaj-c0b3316d43eb44b2a27f63b23e98b5d72020-11-24T21:09:01ZengMDPI AGInorganics2304-67402018-12-016412910.3390/inorganics6040129inorganics6040129Targeted Contrast Agents for Molecular MRISara Lacerda0Centre de Biophysique Moléculaire, Rue Charles Sadron, 45071 Orléans CEDEX 2, FranceMolecular magnetic resonance imaging (MRI) provides information non-invasively at cellular and molecular levels, for both early diagnosis and monitoring therapeutic follow-up. This imaging technique requires the development of a new class of contrast agents, which signal changes (typically becomes enhanced) when in presence of the cellular or molecular process to be evaluated. Even if molecular MRI has had a prominent role in the advances in medicine over the past two decades, the large majority of the developed probes to date are still in preclinical level, or eventually in phase I or II clinical trials. The development of novel imaging probes is an emergent active research domain. This review focuses on gadolinium-based specific-targeted contrast agents, providing rational design considerations and examples of the strategies recently reported in the literature.https://www.mdpi.com/2304-6740/6/4/129MRImolecular imagingtargeted contrast agentlanthanideprotein-based contrast agent |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sara Lacerda |
spellingShingle |
Sara Lacerda Targeted Contrast Agents for Molecular MRI Inorganics MRI molecular imaging targeted contrast agent lanthanide protein-based contrast agent |
author_facet |
Sara Lacerda |
author_sort |
Sara Lacerda |
title |
Targeted Contrast Agents for Molecular MRI |
title_short |
Targeted Contrast Agents for Molecular MRI |
title_full |
Targeted Contrast Agents for Molecular MRI |
title_fullStr |
Targeted Contrast Agents for Molecular MRI |
title_full_unstemmed |
Targeted Contrast Agents for Molecular MRI |
title_sort |
targeted contrast agents for molecular mri |
publisher |
MDPI AG |
series |
Inorganics |
issn |
2304-6740 |
publishDate |
2018-12-01 |
description |
Molecular magnetic resonance imaging (MRI) provides information non-invasively at cellular and molecular levels, for both early diagnosis and monitoring therapeutic follow-up. This imaging technique requires the development of a new class of contrast agents, which signal changes (typically becomes enhanced) when in presence of the cellular or molecular process to be evaluated. Even if molecular MRI has had a prominent role in the advances in medicine over the past two decades, the large majority of the developed probes to date are still in preclinical level, or eventually in phase I or II clinical trials. The development of novel imaging probes is an emergent active research domain. This review focuses on gadolinium-based specific-targeted contrast agents, providing rational design considerations and examples of the strategies recently reported in the literature. |
topic |
MRI molecular imaging targeted contrast agent lanthanide protein-based contrast agent |
url |
https://www.mdpi.com/2304-6740/6/4/129 |
work_keys_str_mv |
AT saralacerda targetedcontrastagentsformolecularmri |
_version_ |
1716758866121719808 |